Douglas P. Yee

Douglas P. Yee

Oncology

909 Fulton Street Southeast
Minneapolis, MN 55455

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 141 publications

Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.

Correction: ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.

Journal: Annals of surgical oncology

Published: September 05, 2026

Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Correction: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Journal: Annals of surgical oncology

Published: September 04, 2026

Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.

Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.

Journal: medRxiv : the preprint server for health sciences

Published: August 20, 2026

ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.

ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.

Journal: Annals of surgical oncology

Published: July 31, 2026

ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.

ASO Visual Abstract: Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy in the I-SPY2 Trial.

Journal: Annals of surgical oncology

Published: July 31, 2026

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 30, 2026

mRNA and protein expression of fetal insulin receptor in breast cancer cell lines and tissues.

mRNA and protein expression of fetal insulin receptor in breast cancer cell lines and tissues.

Journal: Breast cancer research and treatment

Published: May 21, 2026

Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Journal: Annals of surgical oncology

Published: April 28, 2026

Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.

Journal: Annals of surgical oncology

Published: April 28, 2026

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Journal: Research square

Published: February 23, 2026

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial.

Journal: Research square

Published: February 23, 2026

mRNA and Protein Expression of Fetal Insulin Receptor in Breast Cancer Cell Lines.

mRNA and Protein Expression of Fetal Insulin Receptor in Breast Cancer Cell Lines.

Journal: bioRxiv : the preprint server for biology

Published: December 31, 2025

Showing 1-12 of 141

Last Updated: 09/26/2026